MicroPort Orthopedics, a US division of Shanghai’s medical device maker, MicroPort Scientific, launched the Evolution® NitrX™ Medial-Pivot Knee System, the latest version of its knee replacement product. The newest NitrX™ product features a...
Read moreI-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces on June 24, 2019, that the first patient has...
Read moreDrugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses...
Read moreNovena Global Lifecare, a Singapore company with 250 aesthetic clinics and sales outlets in southeast Asia, will receive an investment of up to $20 million from Sinopharm Capital and Cedarlake Capital. Founded in 2010, Novena is one of the...
Read moreChina’s Amoy Diagnostics will partner with Loxo Oncology, a developer of targeted cancer drugs owned by Eli Lilly and Company, to supply it with accompanying reagents for genetic diagnosis during clinical trials of new drugs in Asia. The...
Read moreTarget Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US and China while...
Read moreTerns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic...
Read moreEddingpharm in-licensed greater China rights to a treatment for thrombocytopenia, a side-effect of liver disease, from Shionogi of Japan. People with thrombocytopenia suffer from a low platelet count and are usually treated with via blood...
Read moreXW Labs of Wuhan received US Orphan Drug Designation status for its lead molecule, a clinical-stage treatment for narcolepsy. XW develops novel small molecule therapeutics for CNS disorders. Narcolepsy, an orphan disease that affects 1 in 2,000...
Read moreEmployer medical costs are projected to rise by 6% next year, according to PwC. The rate of increase is a four-year high, due in part to rising drug prices. The jump is attributed to expensive specialty drugs that weren’t available a few years...
Read moreThis week marked initial public offering (IPO) news from six biopharma companies. Here’s a look. BridgeBio Pharma. On June 17, BridgeBio set terms for its $240 million IPO. The company is based in Palo, Alto, Calif. and is expected to trade on...
Read moreGracell Biotechnologies, a Suzhou immunotherapy company, announced positive preliminary results from a trial of its FasT CAR-19 investigational cell gene therapy. Gracell’s FasT CAR product reduces preparation time to 24 hours, compared to...
Read more
